Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.40 |
| ▸ | PGR | P06401 | 4/20 | 0.38 |
| ▸ | CTSD | P07339 | 3/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7540747 | 1.00 | BACE1 (0.41) | BACE1BACE2PGRCTSDPAX8 | |
| SCHEMBL7576035 | 0.94 | BACE1 (0.36) | BACE1BACE2PGRCTSDGRIN2B | |
| SCHEMBL7544880 | 0.94 | BACE1 (0.36) | BACE1BACE2PGRCTSDGRIN2B | |
| SCHEMBL7552507 | 0.92 | BACE1 (0.40) | BACE1BACE2PGRCTSDBRD4 | |
| SCHEMBL8211503 | 0.92 | PGR (0.39) | BACE1BACE2PGRAR | |
| SCHEMBL7565952 | 0.92 | PGR (0.39) | BACE1BACE2PGRAR | |
| SCHEMBL13054499 | 0.92 | BACE1 (0.45) | BACE1BACE2PGRCTSDBRD4 | |
| SCHEMBL8203038 | 0.92 | PGR (0.39) | BACE1BACE2PGRAR | |
| SCHEMBL7580936 | 0.92 | BACE1 (0.45) | BACE1BACE2PGRCTSDBRD4 | |
| SCHEMBL13054039 | 0.92 | BACE1 (0.40) | BACE1BACE2PGRCTSDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885BACE2 30/4885PGR 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.